Compare FOSL & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOSL | PLX |
|---|---|---|
| Founded | 1984 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 168.1M |
| IPO Year | 1993 | 1998 |
| Metric | FOSL | PLX |
|---|---|---|
| Price | $3.61 | $2.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $12.00 |
| AVG Volume (30 Days) | 424.8K | ★ 777.6K |
| Earning Date | 03-11-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $1,066,179,000.00 | $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ N/A | $30.11 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $0.86 | $1.32 |
| 52 Week High | $4.40 | $3.10 |
| Indicator | FOSL | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 63.87 |
| Support Level | $3.66 | $1.97 |
| Resistance Level | $4.01 | $2.11 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 10.17 | 89.16 |
Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.